Valuation dashboard for Aurora Cannabis Inc. (ACB) with P/E N/A, P/B 0.60, EV/EBITDA -3.37 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Aurora Cannabis Inc. is a leading company in the global cannabis industry, focusing on the cultivation, production, and sale of various cannabis and cannabis-derived products across Canada and internationally. Beyond its core product offerings, the company engages in a broad spectrum of related activities, including the design and engineering of facilities, cannabis breeding programs, research and development, and both wholesale and retail distribution channels.
Analysis Summary
Aurora Cannabis Inc. reported revenue of $320.6M in the most recent fiscal year, growing at a 5-year CAGR of 5.5%.
Trailing-twelve-month margins: gross margin 32.1%, operating margin -29.7%, net margin -38.2%.
At the current price of $3.83, ACB has negative trailing earnings (P/E not meaningful) and an ROE of -21.00%. Market capitalisation stands at $237M.
Balance sheet quality for ACB: current ratio of 5.9. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.60 |
| EV / EBITDA | -3.37 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-18.54 |
| vs Current Price | -584.1% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ACB | Aurora Cannabis Inc. | $237M | 0.60 | -21.0% | |
| TAK | Takeda Pharmaceutical Company Limited | $59.4B | 51.19 | 1.21 | 2.6% |
| TEVA | Teva Pharmaceutical Industries Limited | $45.0B | 61.47 | 5.82 | 17.8% |
| HLN | Haleon plc | $40.5B | 18.64 | 1.84 | 9.9% |
| 0M3Q.L | Zoetis Inc. | $35.4B | |||
| ZTS | Zoetis Inc. | $30.6B | 11.99 | 9.67 | 69.3% |
| HLN.L | Haleon plc | $29.4B | 18.73 | 1.85 | 9.9% |
| 0SAN.L | Sandoz Group AG | $28.3B | 52.81 | 3.84 | 7.0% |
Price
| Price | $3.83 |
| Market Cap | $237M |
| Exchange | NASDAQ |
| Country | CA |
Profitability
| Return on Equity | -21.00% |
| Return on Invested Capital | -15.55% |
| Return on Assets | -17.83% |
| Gross Margin | 32.08% |
| Operating Margin | -29.66% |
| Net Margin | -38.15% |
Related companies: ACRS · BIOA · CGC · EDIT · HITI · IRWD · LFCR
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of ACB: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks